ANGPTL3

There are 54 papers on ANGPTL3 in aging research: 6 trials and 11 observational studies in people, 1 in animals, 1 in cells, 35 reviews. The newest story, Nov 9, 2026: “Genetic study links two proteins to different cardiovascular risks”.

Gene

54 papers study it10 findings

HGNCNCBI GeneTaxon

13 new papers in 30 daysSee all 54 papers on ANGPTL3

At a glance

The findings reach people, from one lab or study. 4 independent labs in 2 countries; 9 trials, 1 with no results posted.

“Proteomic analyses identified ANGPTL3, CST3 and TNFSF8 as the candidate risk-related biomarkers associated with future incident SLE.”
Frailty phenotype, genetic risk and long-term incident systemic lupus erythematosus risk: Insights from the UK Biobank study integrated with multi-omics analysisClinical medicine (London, England)2026doi:10.1016/j.clinme.2026.100598

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 4 independent labs in 2 countries
  • 9 trials, 1 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 9 of 9 trials sponsored by developers of drugs aimed at it
  • Human trial6
  • Humans11
  • Animals1
  • Cells1

Effects

3

LIPG

downin humans1

1 study
  1. ANGPTL3 inhibits LIPG in humans.

    “ANGPTL3 influences triglycerides, LDL-C, and high-density lipoprotein cholesterol through inhibition of lipoprotein lipase and endothelial lipase.”

    Review

    ANGPTL3 and residual atherosclerotic risk: from lipid metabolism to therapeutic targeting

    Frontiers in endocrinology

More on LIPG

LPL

downin humans1

1 study
  1. ANGPTL3 inhibits LPL in humans.

    “ANGPTL3 influences triglycerides, LDL-C, and high-density lipoprotein cholesterol through inhibition of lipoprotein lipase and endothelial lipase.”

    Review

    ANGPTL3 and residual atherosclerotic risk: from lipid metabolism to therapeutic targeting

    Frontiers in endocrinology

More on LPL

Lipid and ceramide metabolism

mediatesin reviews1

1 study
  1. ANGPTL3 mediates lipid and ceramide metabolism.

    “ANGPTLs-particularly the triad ANGPTL3, 4, and 8-have an established role in lipid metabolism through the regulation of triacylglycerol trafficking according to the nutritional status.”

    Review

    Angiopoietin-Like Proteins: Cardiovascular Biology and Therapeutic Targeting for the Prevention of Cardiovascular Diseases

    The Canadian journal of cardiology

More on Lipid and ceramide metabolism

Associations

7

Abdominal aortic aneurysm risk

downin humans1

1 study
  1. ANGPTL3 is associated with abdominal aortic aneurysm risk in humans (Genetically proxied ANGPTL3 inhibition).

    “genetically-proxied ANGPTL3 inhibition had minimal association with CAD, PAD, AS and a modest association with lower AAA risk.”

    HumansGenetically proxied ANGPTL3 inhibition

    Genetic study links two proteins to different cardiovascular risks

    AHA Scientific Sessions 2026 abstract

More on Abdominal aortic aneurysm risk

Risk of coronary artery disease, peripheral artery disease, and aortic stenosis

no changein humans1

1 study
  1. ANGPTL3 is associated with risk of coronary artery disease, peripheral artery disease, and aortic stenosis in humans (Genetically proxied ANGPTL3 inhibition) (Minimal association).

    “genetically-proxied ANGPTL3 inhibition had minimal association with CAD, PAD, AS and a modest association with lower AAA risk.”

    HumansGenetically proxied ANGPTL3 inhibition

    Genetic study links two proteins to different cardiovascular risks

    AHA Scientific Sessions 2026 abstract

More on Risk of coronary artery disease, peripheral artery disease, and aortic stenosis

Chronic kidney disease

downin humans1OR 0.76

1 study
  1. ANGPTL3 is linked with a lower risk of chronic kidney disease in humans (genetically proxied inhibition; per 1-SD decrease in triglycerides) (OR 0.76 [95% CI 0.69 to 0.84]).

    “genetically proxied ANGPTL3 inhibition, ANGPTL4 inhibition, and lipoprotein lipase enhancement were associated with lower CKD risk”

    Humansgenetically proxied inhibition; per 1-SD decrease in triglycerides

    Genetic study links protein inhibition to lower kidney disease risk

    American journal of kidney diseases : the official journal of the National Kidney Foundation

More on Chronic kidney disease

Systemic lupus erythematosus

upin humans1

1 study
  1. ANGPTL3 is associated with systemic lupus erythematosus in humans.

    “Proteomic analyses identified ANGPTL3, CST3 and TNFSF8 as the candidate risk-related biomarkers associated with future incident SLE.”

    Humansn = 462,762

    Frailty phenotype, genetic risk and long-term incident systemic lupus erythematosus risk: Insights from the UK Biobank study integrated with multi-omics analysis

    Clinical medicine (London, England)

More on Systemic lupus erythematosus

Renal cell carcinoma

upin humans1OR 1.975

1 study
  1. ANGPTL3 is linked with a higher risk of renal cell carcinoma in humans (genetically proxied inhibition, drug-target Mendelian randomization) (OR 1.975 (95% CI 1.217-3.205)).

    “ANGPTL3 inhibition was also associated with an increased risk of renal cell carcinoma (OR =1.975; 95% CI: 1.217-3.205)”

    Humansgenetically proxied inhibition, drug-target Mendelian randomization

    The role of lipid-lowering drugs in urologic and male reproductive cancers: a Mendelian randomization study

    Translational andrology and urology

More on Renal cell carcinoma

Prostate cancer

upin humans1OR 1.365

1 study
  1. ANGPTL3 is linked with a higher risk of prostate cancer in humans (genetically proxied inhibition, drug-target Mendelian randomization) (OR 1.365 (95% CI 1.091-1.709)).

    “Genetically proxied inhibition of ANGPTL3 was associated with a higher risk of prostate cancer [odds ratio (OR) =1.365; 95% confidence interval (CI): 1.091-1.709]”

    Humansgenetically proxied inhibition, drug-target Mendelian randomization

    The role of lipid-lowering drugs in urologic and male reproductive cancers: a Mendelian randomization study

    Translational andrology and urology

More on Prostate cancer

Colorectal cancer

downin humans1

1 study
  1. ANGPTL3 is linked with a lower risk of colorectal cancer in humans (genetically proxied lipid-lowering variants (Mendelian randomization); also LDLR).

    “Lipid-lowering variants of ANGPTL3 and LDLR were associated with reduced risks of colorectal cancer”

    Humansgenetically proxied lipid-lowering variants (Mendelian randomization); also LDLR

    Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study

    Aging

More on Colorectal cancer

Funding

2 grants since 2020

National Heart, Lung, and Blood Institute$87.6KNatural Sciences and Engineering Research CouncilCA$4.5K

Latest

Dec 2025: 1Jan 2026: 6Feb 2026: 5Mar 2026: 3Apr 2026: 1May 2026: 0Jun 2026: 1Jul 2026: 3Aug 2026: 1Sep 2026: 6Oct 2026: 8Nov 2026: 742 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Genetic study links two proteins to different cardiovascular risks

Human genetic analyses linked lower activity of one fat-regulating protein to lower risks of four cardiovascular diseases, while a related protein showed little…Human genetic analyses linked lower activity of one fat-regulating protein to lower risks of four cardiovascular diseases, while a related protein showed little association with three.

Mendelian randomizationMechanisms

See all 54 papers on ANGPTL3